Drug synergism was measured using the Loewe model with Combenefit software (Cancer Research UK Cambridge Institute), and the combination index was calculated using CompuSyn software (ComboSyn) ( 3 Results 3.1 CB-839 treatment inhibits glutathione synthesis and the conversion of glutamine to glutamate in CLL cell lines Initially, we investigated CB-839s functional inhibition of GLS-1 ( Figures 1A, B )
Animal Model:Wistar Albino (male, 200-220 g body weight) [3] Dosage:10 g/kg, 10 ng/kg (catalepsy and gastric ulcers)
Gene expression modulation studies (over 4,000 human genes documented)
BPC+TB Blend is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications
frequently bundled into longevity narratives